ASH2023注目テーマ⑧ 注目演題「#425」

NPM1変異陽性AMLに対するCR1での同種移植
FLT3-ITD変異にかかわらずMRD陽性例で有用 The Benefit of Allogeneic Transplant in 1st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction–an Analysis of the UK NCRI AML17 and AML19 Studies (#425)

Jad Othman（Department of Medical and Molecular Genetics, King's College London, London, United Kingdom）